TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicentre Study to Evaluate the Immunogenicity and Safety of GSK Biologicals' HPV Vaccine (580299) Co-administered With Boostrix Polio (dTpa-IPV) in Healthy Female Subjects Aged 10-18 Years
Brief Summary: Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. Vaccination of pre-teens and adolescents, ideally before sexual debut and thus before exposure to oncogenic HPV, is a rational strategy for prevention of cervical cancer, and so HPV vaccination could complement the existing pre-adolescent/adolescents platform. Therefore, this Phase IIIb study is designed to evaluate the safety and immunogenicity of co-administering Boostrix polio (dTpa-IPV) with GSK Biologicals' (580299)HPV-16/18 L1 AS04 vaccine (Cervarix TM) as compared to the administration of either vaccine alone.

The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.


Options:
A: Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: GSK Biologicals' HPV-16/18 L1 AS04 vaccine (Cervarix TM) | Arm Label: Boostrix Polio → Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: Boostrix ® Polio, Biological: GSK Biologicals' HPV-16/18 L1 AS04 vaccine (Cervarix TM) | Arm Label: Cervarix + Boostrix Polio Group; Type: EXPERIMENTAL; Interventions: Biological: Boostrix ® Polio, Biological: GSK Biologicals' HPV-16/18 L1 AS04 vaccine (Cervarix TM) | Intervention Type: BIOLOGICAL; Name: Boostrix ® Polio; Assigned to Arm(s): Boostrix Polio → Cervarix Group, Cervarix + Boostrix Polio Group | Intervention Type: BIOLOGICAL; Name: GSK Biologicals' HPV-16/18 L1 AS04 vaccine (Cervarix TM); Assigned to Arm(s): Boostrix Polio → Cervarix Group, Cervarix + Boostrix Polio Group, Cervarix Group
B: Intervention Type: BIOLOGICAL; Name: HPV-16/18 L1/AS04; Assigned to Arm(s): N/A
C: Arm Label: Cervarix Group; Type: OTHER; Interventions: Procedure: Blood sampling | Intervention Type: PROCEDURE; Name: Blood sampling; Assigned to Arm(s): Cervarix Group
D: Arm Label: qHPV Vaccine in Base Study; Type: EXPERIMENTAL; Interventions: Biological: V501 | Arm Label: Placebo in Base Study; Type: PLACEBO_COMPARATOR; Interventions: Biological: Comparator: Placebo | Arm Label: qHPV Vaccine in Extension Study; Type: EXPERIMENTAL; Interventions: Biological: V501 | Intervention Type: BIOLOGICAL; Name: V501; Assigned to Arm(s): qHPV Vaccine in Base Study, qHPV Vaccine in Extension Study | Intervention Type: BIOLOGICAL; Name: Comparator: Placebo; Assigned to Arm(s): Placebo in Base Study

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-Week, Randomized, Double-Blind, Multi-Center, Vehicle-Controlled, Parallel Group Study to Assess the Efficacy and Safety of the Diclofenac Sodium Gel 1% for the Relief of Signs and Symptoms in Patients With Osteoarthritis of the Knee.
Brief Summary: This study will test the efficacy and safety of topical diclofenac sodium gel in the treatment of knee osteoarthritis.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: ketoprofen in Diractin® | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: ketoprofen in Diractin® | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: celecoxib | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: ketoprofen in Diractin®; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: ketoprofen in Diractin®; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4 | Intervention Type: DRUG; Name: celecoxib; Assigned to Arm(s): 3
B: Intervention Type: DRUG; Name: Diclofenac Topical Sodium Gel 1%; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Diclofenac Topical Sodium Gel 1%; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Diclofenac Sodium Gel | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Diclofenac Sodium Gel; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-Week, Randomized, Double-Blind, Multi-Center, Vehicle-Controlled, Parallel Group Study to Assess the Efficacy and Safety of the Diclofenac Sodium Gel 1% for the Relief of Signs and Symptoms in Patients With Osteoarthritis of the Knee.
Brief Summary: This study will test the efficacy and safety of topical diclofenac sodium gel in the treatment of knee osteoarthritis.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Diclofenac Sodium Gel | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Diclofenac Sodium Gel; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Intervention Type: DRUG; Name: Diclofenac Topical Sodium Gel 1%; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Diclofenac Topical Sodium Gel 1%; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Diclofenac topical sodium gel 1%; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Resistance Training on Cognitive Performance, Cortical Plasticity, and Fall Risk in Women Aged 65-75 Years Old: A 12-Month RCT
Brief Summary: Primary Objectives:

1. To ascertain whether a 12-month, twice-weekly or once-weekly resistance training (RT) program will significantly improve executive function in community-dwelling women aged 65 to 75 years old compared with a 12-month, twice-weekly stretch and relax (S \& R) program (shame exercise). We will assess executive function by standard neuropsychological tests.

Secondary Objectives:

1. To describe the neural mechanisms that underpin the observed changes in executive function associated with a 12-month, twice-weekly or once-weekly RT training (by using functional magnetic resonance imaging (fMRI)).
2. To investigate whether RT-induced changes in executive function are independently associated with changes in physiological fall risk profile.
3. To investigate the dose response of RT (resistance training) on bone health as measured by dual energy x-ray and peripheral quantitative computed tomography.
4. To conduct a one-year follow-up after the formal cessation of the resistance training programs to determine the persisting effect of resistance training on cognitive performance, cortical plasticity, physiological falls risk, and bone health.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise Training | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise training | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise training | Intervention Type: BEHAVIORAL; Name: Exercise Training; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Exercise training; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Exercise training; Assigned to Arm(s): 3
B: Intervention Type: BEHAVIORAL; Name: physical exercise, wellness; Assigned to Arm(s): N/A
C: Arm Label: ActiveStep; Type: ACTIVE_COMPARATOR; Interventions: Device: ActiveStep Treadmill | Arm Label: Standard physical therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: Physical Therapy | Intervention Type: DEVICE; Name: ActiveStep Treadmill; Assigned to Arm(s): ActiveStep | Intervention Type: OTHER; Name: Physical Therapy; Assigned to Arm(s): Standard physical therapy
D: Arm Label: TT+VR; Type: EXPERIMENTAL; Interventions: Other: TT+VR | Arm Label: TT alone; Type: ACTIVE_COMPARATOR; Interventions: Other: TT alone | Intervention Type: OTHER; Name: TT+VR; Assigned to Arm(s): TT+VR | Intervention Type: OTHER; Name: TT alone; Assigned to Arm(s): TT alone

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Resistance Training on Cognitive Performance, Cortical Plasticity, and Fall Risk in Women Aged 65-75 Years Old: A 12-Month RCT
Brief Summary: Primary Objectives:

1. To ascertain whether a 12-month, twice-weekly or once-weekly resistance training (RT) program will significantly improve executive function in community-dwelling women aged 65 to 75 years old compared with a 12-month, twice-weekly stretch and relax (S \& R) program (shame exercise). We will assess executive function by standard neuropsychological tests.

Secondary Objectives:

1. To describe the neural mechanisms that underpin the observed changes in executive function associated with a 12-month, twice-weekly or once-weekly RT training (by using functional magnetic resonance imaging (fMRI)).
2. To investigate whether RT-induced changes in executive function are independently associated with changes in physiological fall risk profile.
3. To investigate the dose response of RT (resistance training) on bone health as measured by dual energy x-ray and peripheral quantitative computed tomography.
4. To conduct a one-year follow-up after the formal cessation of the resistance training programs to determine the persisting effect of resistance training on cognitive performance, cortical plasticity, physiological falls risk, and bone health.


Options:
A: Intervention Type: BEHAVIORAL; Name: physical exercise, wellness; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Fall prevention course | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Fall prevention course; Assigned to Arm(s): 1
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise Training | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise training | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise training | Intervention Type: BEHAVIORAL; Name: Exercise Training; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Exercise training; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Exercise training; Assigned to Arm(s): 3
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: multifactorial intervention | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Usual care | Intervention Type: OTHER; Name: multifactorial intervention; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III Randomized Trial of Local Excision Versus Total Mesorectal Excision in Downstaged T2T3 Low Rectal Cancer After Radiochemotherapy
Brief Summary: Patients with T2T3 low rectal cancer (size =\< 4 cm) received neoadjuvant treatment (50Gy in 5 weeks with concomitant chemotherapy. Good responders (residual tumour =\< 2 cm) are randomised in local vs rectal excision, 6-8 weeks after treatment. The composite end point evaluates the rate of patients with death, recurrence, major morbidity or severe after effects at two years.


Options:
A: Intervention Type: DRUG; Name: fluorouracil; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: leucovorin calcium; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: local rectal excision | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: total mesorectal excision | Intervention Type: PROCEDURE; Name: local rectal excision; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: total mesorectal excision; Assigned to Arm(s): 2
C: Arm Label: 1; Type: OTHER; Interventions: Procedure: surgery | Intervention Type: PROCEDURE; Name: surgery; Assigned to Arm(s): 1
D: Arm Label: Total Mesorectal Excision; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Additional TME surgery | Arm Label: Adjuvant chemoradiotherapy; Type: EXPERIMENTAL; Interventions: Radiation: Adjuvant chemoradiotherapy, Drug: capecitabine | Intervention Type: RADIATION; Name: Adjuvant chemoradiotherapy; Assigned to Arm(s): Adjuvant chemoradiotherapy | Intervention Type: PROCEDURE; Name: Additional TME surgery; Assigned to Arm(s): Total Mesorectal Excision | Intervention Type: DRUG; Name: capecitabine; Assigned to Arm(s): Adjuvant chemoradiotherapy

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase IV Study of Perioperative Steroid's Effects on Death or MI in High-Risk Patients Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass
Brief Summary: SIRS trial is a large simple study in which high-risk patients undergoing cardiac surgery requiring the use of cardiopulmonary bypass (CPB) are randomly allocated to receive a pulse dose of Methylprednisolone or a matching placebo. Cardiopulmonary bypass initiates a systemic inflammatory response that facilitates development of post-operative complications. SIRS will confirm or deny the potential clinical benefits of suppressing this response through the use of systemic steroids. Specifically, does 250 mg of intravenous Methylprednisolone given twice, once on anesthetic induction and again on CPB initiation, result in improved early survival and less myocardial infarction in high-risk cardiac surgery patients requiring CPB?


Options:
A: Arm Label: Sevoflurane Group; Type: N/A; Interventions: Drug: Sevoflurane | Arm Label: Not Sevoflurane Group; Type: N/A; Interventions: N/A | Intervention Type: DRUG; Name: Sevoflurane; Assigned to Arm(s): Sevoflurane Group
B: Arm Label: Interventional group; Type: EXPERIMENTAL; Interventions: Device: hemoadsorber for removal of cytokines | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: hemoadsorber for removal of cytokines; Assigned to Arm(s): Interventional group
C: Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Drug: Methylprednisolone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Methylprednisolone; Assigned to Arm(s): Treatment | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: epoetinum | Intervention Type: DRUG; Name: epoetinum; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase IV Study of Perioperative Steroid's Effects on Death or MI in High-Risk Patients Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass
Brief Summary: SIRS trial is a large simple study in which high-risk patients undergoing cardiac surgery requiring the use of cardiopulmonary bypass (CPB) are randomly allocated to receive a pulse dose of Methylprednisolone or a matching placebo. Cardiopulmonary bypass initiates a systemic inflammatory response that facilitates development of post-operative complications. SIRS will confirm or deny the potential clinical benefits of suppressing this response through the use of systemic steroids. Specifically, does 250 mg of intravenous Methylprednisolone given twice, once on anesthetic induction and again on CPB initiation, result in improved early survival and less myocardial infarction in high-risk cardiac surgery patients requiring CPB?


Options:
A: Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Drug: Methylprednisolone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Methylprednisolone; Assigned to Arm(s): Treatment | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Inhalational anesthetic; Type: ACTIVE_COMPARATOR; Interventions: Drug: Inhalational anesthetic | Arm Label: Intravenous anesthetic, propofol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravenous anesthetic, propofol | Intervention Type: DRUG; Name: Inhalational anesthetic; Assigned to Arm(s): Inhalational anesthetic | Intervention Type: DRUG; Name: Intravenous anesthetic, propofol; Assigned to Arm(s): Intravenous anesthetic, propofol
C: Arm Label: Dexamethasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexamethasone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Dexamethasone | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Dexamethasone, Placebo
D: Arm Label: Deeper sedation; Type: ACTIVE_COMPARATOR; Interventions: Device: Deeper sedation | Arm Label: Moderate sedation; Type: ACTIVE_COMPARATOR; Interventions: Device: Moderate sedation | Intervention Type: DEVICE; Name: Deeper sedation; Assigned to Arm(s): Deeper sedation | Intervention Type: DEVICE; Name: Moderate sedation; Assigned to Arm(s): Moderate sedation

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase IV Study of Perioperative Steroid's Effects on Death or MI in High-Risk Patients Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass
Brief Summary: SIRS trial is a large simple study in which high-risk patients undergoing cardiac surgery requiring the use of cardiopulmonary bypass (CPB) are randomly allocated to receive a pulse dose of Methylprednisolone or a matching placebo. Cardiopulmonary bypass initiates a systemic inflammatory response that facilitates development of post-operative complications. SIRS will confirm or deny the potential clinical benefits of suppressing this response through the use of systemic steroids. Specifically, does 250 mg of intravenous Methylprednisolone given twice, once on anesthetic induction and again on CPB initiation, result in improved early survival and less myocardial infarction in high-risk cardiac surgery patients requiring CPB?


Options:
A: Arm Label: Methylprednisolone Arm; Type: EXPERIMENTAL; Interventions: Drug: Methylprednisolone | Arm Label: Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Isotonic saline | Intervention Type: DRUG; Name: Methylprednisolone; Assigned to Arm(s): Methylprednisolone Arm | Intervention Type: DRUG; Name: Isotonic saline; Assigned to Arm(s): Placebo Arm
B: Arm Label: Single dose steroid; Type: EXPERIMENTAL; Interventions: Drug: methylprednisolone (IVMP) | Arm Label: Two Dose steroid; Type: EXPERIMENTAL; Interventions: Drug: methylprednisolone (two doses IVMP) | Intervention Type: DRUG; Name: methylprednisolone (IVMP); Assigned to Arm(s): Single dose steroid | Intervention Type: DRUG; Name: methylprednisolone (two doses IVMP); Assigned to Arm(s): Two Dose steroid
C: Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Drug: Methylprednisolone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Methylprednisolone; Assigned to Arm(s): Treatment | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Dexamethasone; Type: EXPERIMENTAL; Interventions: Drug: Dexamethasone | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Dexamethasone | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Control

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Received BCG Immunisation 1 Month Previously
Brief Summary: This is a phase I study to test the immunogenicity of a recombinant vaccine based on Modified Vaccinia Ankara (MVA) expressing the antigen 85A (from Mycobacterium tuberculosis). This vaccine is delivered intradermally by a needle injection in healthy volunteers previously vaccinated with BCG.


Options:
A: Intervention Type: BIOLOGICAL; Name: MVA85A (Tuberculosis vaccine); Assigned to Arm(s): N/A
B: Intervention Type: BIOLOGICAL; Name: MVA85A; Assigned to Arm(s): N/A
C: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Biological: MVA85A-IMX313 | Arm Label: Group B; Type: ACTIVE_COMPARATOR; Interventions: Biological: MVA85A-IMX313 | Arm Label: Group C; Type: ACTIVE_COMPARATOR; Interventions: Biological: MVA85A | Intervention Type: BIOLOGICAL; Name: MVA85A-IMX313; Assigned to Arm(s): Group A, Group B | Intervention Type: BIOLOGICAL; Name: MVA85A; Assigned to Arm(s): Group C
D: Arm Label: Investigational Vaccine; Type: EXPERIMENTAL; Interventions: Biological: MVA85A/AERAS-485 | Arm Label: Control Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Candida Skin Test Antigen | Intervention Type: BIOLOGICAL; Name: MVA85A/AERAS-485; Assigned to Arm(s): Investigational Vaccine | Intervention Type: BIOLOGICAL; Name: Candida Skin Test Antigen; Assigned to Arm(s): Control Group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo Controlled, Study to Evaluate the Efficacy and Safety of Esomeprazole Once Daily for the Treatment of Gastroesophageal Reflux Disease (GERD) in Neonatal Patients, Including Premature and up to 1 Month Corrected Age
Brief Summary: The purpose of this study is to assess the difference between esomeprazole and placebo in the treatment of signs and symptoms as observed by 8-hour video and cardiorespiratory monitoring in neonatal patients.


Options:
A: Arm Label: Open Label Esomeprazole; Type: EXPERIMENTAL; Interventions: Drug: Open Label Run In Esomeprazole | Arm Label: Double Blind Esomeprazole; Type: EXPERIMENTAL; Interventions: Drug: Double Blind Esomeprazole | Arm Label: Double Blind Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Double Blind Placebo | Intervention Type: DRUG; Name: Open Label Run In Esomeprazole; Assigned to Arm(s): Open Label Esomeprazole | Intervention Type: DRUG; Name: Double Blind Esomeprazole; Assigned to Arm(s): Double Blind Esomeprazole | Intervention Type: DRUG; Name: Double Blind Placebo; Assigned to Arm(s): Double Blind Placebo
B: Arm Label: Low dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: pantoprazole sodium enteric-coated spheroid suspension | Arm Label: High dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: pantoprazole sodium enteric-coated spheroid suspension | Intervention Type: DRUG; Name: pantoprazole sodium enteric-coated spheroid suspension; Assigned to Arm(s): High dose, Low dose
C: Intervention Type: DRUG; Name: Esomeprazole; Assigned to Arm(s): N/A
D: Arm Label: Rabeprazole 0.5 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: rabeprazole | Arm Label: Rabeprazole 1.0 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: rabeprazole | Intervention Type: DRUG; Name: rabeprazole; Assigned to Arm(s): Rabeprazole 0.5 mg/kg | Intervention Type: DRUG; Name: rabeprazole; Assigned to Arm(s): Rabeprazole 1.0 mg/kg

Answer: C